via CCSVI in Multiple Sclerosis - No to Lemtrada. The FDA listens to their medical advisory panel and rejects Lemtrada--citing serious infections, malignancies and other autoimmune diseases in patients taking Lemtrada. They also remark that the clinical trials were "fatally flawed"--since they were open label and not blinded.https://www.facebook.com/permalink.php?story_fbid=10152112602152298&id=110796282297&notif_t=notify_me


FDA spurns Sanofi's Lemtrada on fatally flawed PhIII design
www.fiercebiotech.com
Sanofi has been slammed against the regulatory wall at the FDA, picking up a stinging rejection of its multiple sclerosis drug Lemtrada with orders to go back to the clinic for a major round of new...